RPRX Royalty Pharma plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802768 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.4%
TTM net income YoY-12.1%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR4.0%
Net income 3-yr CAGR53.8%
Margins
Gross margin—
Operating margin57.1%
Net margin25.7%
FCF margin—
EBITDA margin57.3%
Returns
ROE10.1%
ROA3.5%
ROIC (approx.)10.2%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity1.26x
Current ratio1.29x
Interest coverage4.02x
Cash quality & payout
Operating cash flow / net income4.41x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $690.10M | $674.14M | $630.58M | $621.99M | $609.29M | $578.66M | $568.25M | $593.64M |
| R&D expense | $63.16M | $97.85M | $39.79M | $50.50M | $50.50M | $300.50M | $50.50M | $500,000 |
| SG&A expense | $150.10M | $161.89M | $159.49M | $164.27M | $118.73M | $179.77M | $110.70M | $67.59M |
| Operating income | $410.84M | $133.12M | $563.04M | $388.38M | $427.16M | $209.80M | $534.18M | $361.51M |
| Interest expense | $90.49M | $93.62M | $93.72M | $94.17M | $79.56M | $68.67M | $65.26M | $65.76M |
| Pretax income | $266.64M | $81.49M | $468.26M | $355.91M | $440.21M | $92.64M | $434.43M | $334.35M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $144.68M | $17.88M | $294.69M | $214.21M | $284.22M | $32.18M | $239.35M | $208.21M |
| EBITDA | $412.06M | $134.41M | $564.21M | $389.58M | $428.43M | $211.18M | $534.18M | $361.51M |
| EPS (basic) | 0.32 | 0.04 | 0.67 | — | 0.66 | 0.08 | 0.55 | — |
| EPS (diluted) | 0.32 | 0.04 | 0.67 | — | 0.66 | 0.07 | 0.55 | — |
| Dividends declared per share | 0.23 | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 |
| Weighted avg. shares (diluted) | 557.00M | 556.90M | 556.84M | — | 559.61M | 562.30M | 578.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $513.66M | $811.99M | $586.39M | $618.70M | $938.94M | $631.91M | $1.09B | $929.03M |
| Short-term investments | $31.20M | $25.00M | $21.90M | $18.80M | $16.10M | $13.20M | $12.10M | $58.20M |
| Current assets | $1.53B | $1.76B | $1.43B | $1.53B | $1.85B | $1.52B | $1.84B | $1.80B |
| Goodwill | $923.53M | $923.53M | $924.63M | $924.63M | $924.63M | $924.63M | — | $0 |
| Total assets | $19.46B | $19.82B | $19.82B | $19.62B | $19.35B | $18.32B | $17.61B | $18.22B |
| Current liabilities | $1.18B | $630.93M | $535.68M | $636.21M | $530.80M | $1.21B | $1.18B | $1.25B |
| Short-term debt | $996.97M | $380.00M | $380.00M | $380.00M | $380.00M | $999.44M | $998.61M | $997.77M |
| Long-term debt | $7.59B | $8.58B | $8.58B | $8.57B | $8.57B | $7.00B | $6.62B | $6.61B |
| Total debt | $8.59B | $8.96B | $8.96B | $8.95B | $8.95B | $8.00B | $7.62B | $7.61B |
| Total liabilities | $9.67B | $10.03B | $9.88B | $9.91B | $9.73B | $8.82B | $7.82B | $7.88B |
| Shareholders' equity | $6.84B | $6.83B | $6.89B | $6.48B | $6.40B | $6.34B | $6.68B | $6.95B |
| Net debt | $8.07B | $8.15B | $8.37B | $8.33B | $8.01B | $7.37B | $6.53B | $6.68B |
| Cash flow statement | ||||||||
| Operating cash flow | $686.08M | $728.46M | $718.23M | $827.15M | $702.62M | $363.98M | $596.08M | $742.52M |
| Investing cash flow | -$285.66M | -$229.72M | -$477.87M | -$847.80M | -$958.31M | -$311.98M | $503.92M | -$505.59M |
| Financing cash flow | -$698.74M | -$273.15M | -$272.67M | -$299.60M | $562.74M | -$507.81M | -$941.30M | -$257.96M |
| Depreciation & amortization | $1.22M | $1.29M | $1.17M | $1.20M | $1.28M | $1.38M | $0 | $0 |
| Stock-based compensation | $105.15M | $107.36M | $121.99M | $125.77M | $73.35M | $91.04M | $515,000 | $525,000 |
| Share buybacks | $86.34M | $44.64M | $50.10M | $80.54M | $146.49M | $291.57M | $708.78M | $52.61M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.